Jump to content

Philip Needleman

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by RAJIVVASUDEV (talk | contribs) at 05:23, 2 January 2021 (Importing Wikidata short description: "American pharmacologist and academic" (Shortdesc helper)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Philip Needleman is an American pharmacologist and academic. Needleman was a professor and associate dean at the Washington University School of Medicine and he served as an executive at Monsanto/Searle. He is credited with discovering the first thromboxane synthase inhibitor, the inflammatory substance known as COX-2 and the cardiac hormone known as atriopeptin. Needleman is a member of the National Academy of Sciences and a Fellow of the American Academy of Arts and Sciences.

Biography

Needleman attended the Philadelphia College of Pharmacy and Science, where he earned an undergraduate degree and a master's degree, both in pharmacology. He subsequently studied at the University of Maryland School of Medicine and received a doctoral degree in pharmacology.[1]

He was a postdoctoral fellow at the Washington University School of Medicine, remaining there as a faculty member. He became a full professor and he chaired the pharmacology department from 1976 to 1989.

In 1989 left academia for industry and became vice president of Monsanto.[2] In 1993 he became president of Searle.[2] There he oversaw research into COX-2 that led to the development of the anti-inflammatory drug celecoxib (Celebrex), which was approved in 1998 by the Food and Drug Administration (FDA).[2] He became senior executive vice president and chief scientist of Pharmacia from 2000 to 2003.[2]

He returned to academia as an associate dean at the Washington University School of Medicine in 2004 and was subsequently named to the school's board of trustees.[1] He served as interim president of two institutions, the Donald Danforth Plant Science Center and the Saint Louis Science Center.[3][4]

Needleman was elected to the National Academy of Sciences in 1987 in the physiology and pharmacology section.[5] He received the NAS Award for the Industrial Application of Science in 2005 for his work on "metabolism of arachidonic acid in physiology and pathophysiology, which generates prostacyclin and thromboxane."[6] He was named a fellow of the American Academy of Arts and Sciences in 2015.[7]

References

  1. ^ a b "Needleman elected to American Academy of Arts and Sciences". Washington University School of Medicine. May 1, 2015. Retrieved July 3, 2015.
  2. ^ a b c d "Philip Needleman". National Academy of Sciences. 15 June 2015. Retrieved 28 December 2015.
  3. ^ "Leading plant researcher to lead Danforth Center". Donald Danforth Plant Science Center. November 6, 2010. Retrieved July 3, 2015.
  4. ^ Seltzer, Jo (June 7, 2011). "Scientist thrives on challenge and change". St. Louis Beacon. Archived from the original on July 20, 2013. Retrieved July 3, 2015.
  5. ^ NAS member directory
  6. ^ NAS Award for the Industrial Application of Science Archived 2015-01-08 at the Wayback Machine National Academy of Sciences web site
  7. ^ "Dr. Philip Needleman". American Academy of Arts and Sciences. Retrieved July 3, 2015.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Philip_Needleman&oldid=997779706"